We are grateful for the previous and current support for technology development provided by these forward-looking federal agencies:

By combining natural and designer proteins in cells, Arzeda can then reprogram fermentation hosts to produce virtually any chemical. Arzeda’s Scylax™ software automates pathway design. Leveraging highly annotated proprietary databases, Scylax™ enumerates and ranks all the possible enzymatic routes employing natural and designer enzymes from any specified molecule to a desired target molecule.

Arzeda’s computational protein and pathway design is poised to transform both biocatalysis and fermentation, including biocatalytic manufacturing of difficult-to-synthesize drug intermediates and the sustainable production of fine and specialty chemicals not made in nature. Arzeda’s biological design technologies unlock the value of synthetic systems biology, where complex cellular function can be designed computationally.

From proteins to cellular function: synthetic systems biology

​From technology to impact: scale-up

At Arzeda, we understand that having designer proteins and pathways working in vitro or in flasks is only part of the equation to bring industrially valuable products to market. We are dedicated to working with our industrial partners to not only design, but also scale our products. Thanks to a recent infusion of capital, we are taking aggressive steps to rapidly develop scalable solutions for industrial enzymes, fine and specialty chemicals and other verticals we address. We are also working closely with our commercialization partners and contract manufacturing to access scalable capabilities.
Management

Meet Our Team

Alexandre Zanghellini, PhD

Founder and CEO

Daniela Grabs, PhD

Co-founder and CSO

Eric Althoff, PhD

Co-founder and CBO